Grading Gottlieb: How Attys View FDA Chief's First 6 Months

Law360, New York (November 9, 2017, 10:18 PM EST) -- In Scott Gottlieb's first six months as U.S. Food and Drug Administration chief, he has moved rapidly to streamline approvals and has become something of a rock-star regulator who tweets energetically about everything from gene therapy to skinny jeans.

Gottlieb, who was sworn in as FDA commissioner on May 11, has prioritized quicker approvals of prescription drugs and medical devices, including direct-to-consumer DNA tests and digital health software. In doing so, he has adopted a relatively freewheeling public posture — including an enthusiastic embrace of social media — that has lent a subtle aura of coolness to the wonky world of...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!